Drugs / SRA737
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02797964 | Jul 2016 → Oct 2019 | non-Hodgkin lymphoma | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
| Phase 1/2 | NCT02797977 | Jul 2016 → Apr 2020 | cancer | Sierra Oncology LLC - a GSK company | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRA737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797964 ↗ |
| Known as | CCT-245737 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4169078 ↗ |
| Known as | CCT245737 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4169078 ↗ |
| Known as | PNT-737 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4169078 ↗ |
| Action | Inhibit | “SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1” NCT02797964 ↗ |
| Modality | Small molecule | “SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1” NCT02797964 ↗ |
| Route | Oral | “SRA737 will be administered orally on each day of a 28-day cycle” NCT02797964 ↗ |
| Target | CHEK1 | “SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1” NCT02797964 ↗ |